HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
Remember me:

Opinion: Europe remains a problem for Ramsay

Yesterday’s stock price fall for Ramsay Health Care was not entirely unexpected. Shares in Australia’s largest private hospital operator dropped 5.75% to A$63.90 (US$49.81) after it revealed distinctly unimpressive first half figures.

Profits were down 3.7% to A$246.5 million.

Managing director Craig McNally admitted “ongoing challenges in the operating environment in Europe”. He wasn’t wrong and nor is the outlook expected to get better any time soon.

At the heart of the problem is Ramsay Générale de Santé, its French business, acquired in October 2014. Revenues fell 1.1% to €1.1 billion (US$1.35 billion) and EBITDAR was down 5.8% to €194.1 million.

“We are focused on achieving efficiencies in these businesses and, to this end, we are investing in a major transformation project in our French operations that will centralise non-core hospital resources and distinguish this business for the long term,” he said. Non-core hospital functions such as finance, administration and HR, will be relocated to a separate shared service centre in the outer suburbs of Paris

All good news, but this is not going to start until the second half and is going to take three years. A sign of how disruptive this is going to be is that Ramsay has provided for a restructuring charge of €43.7 million.

Although its presence is smaller, business is not much better in the UK. British revenues fell 4.8% to £206.2 million (US$286.7 million) with EBITDAR down 4.6% to £49.4 million thanks to NHS management demand strategies.

The issue for investors is that there are no discernable upsides in the short term. Pollyannas could point to Australian revenues. Domestic turnover was indeed up 4.3% to A$2.5 billion with a pleasing 9.1% jump in corresponding EBIT, but proposed caps on health insurance premia from the opposition Labor party could soon bring that growth to a shuddering halt.

Demographic trends and an aging population still support the Ramsay business case, but the next couple of years are going to be anything other than easy.

Posted on: 01/03/2018 UTC+08:00


Life sciences company OncoSil Medical is to raise A$18.7 million (US$14.4 million) in a two tranche institutional placement and share purchase plan.
Hong Kong listed hospital services company Hua Xia Healthcare has raised HK$46 million (US$5.9 million) in a private placement. Kingston Securities managed the deal.
AK Medical Holdings, which is the largest artificial orthopaedic joint manufacturer in China, has reported a 36.3% rise in profits for the year to Rmb105.4 million (US$16.7 million) on revenues that rose 37.6% to Rmb372.7 million.
Singapore-based DocDoc, a service which enables both locals and medical tourists to find a doctor or dentist across the region, has raised US$5.45 million in Series B funding. The financing is led by Adamas Finance Asia Limited (Adam), a London listed investment company which invested US$2 million via a convertible bond offering alongside regional family offices and high net worth individuals.
The owners of Australian health imaging company Pro Medicus have sold down significant stakes in the company.
IHH Healthcare, Asia’s largest healthcare company, has acquired a 60% stake in Chengdu Shenton Health Clinic, formerly known as Sincere Chengdu Clinic, from Beijing Yizhi Zhuoxin Corporate Management Information for Rmb12 million (US$1.9 million).
Japanese home care nursing group Longlife Holdings plans to set up a fee-based nursing home in Ikeda-shi, Osaka.
Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, has reported an 37.2% rise in annual profits to US$11 million on revenues that were up 15.9% to US$136.9 million.


Sumit Sharma, head of health & life sciences, Asia Pacific, at Oliver Wyman, and Matt Zafra, engagement manager, health & life sciences, Oliver Wyman, look at the four themes that are going to dominate healthcare this year.
It can sometimes seem that the healthcare sector is a guaranteed money spinner for investors. It has everything going for it. Societal demands and demographics make it a sure thing, say enthusiasts. And investors have become used to the fact that everything it touches turns to gold.
Yesterday’s stock price fall for Ramsay Health Care was not entirely unexpected. Shares in Australia’s largest private hospital operator dropped 5.75% to A$63.90 (US$49.81) after it revealed distinctly unimpressive first half figures.
Susann Roth, senior social development specialist, Asian Development Bank, gives one way how health risks can be lowered at Special Economic Zones.
Nicole Hill, global director of healthcare at ALE, has a goal to make everyone and everything in healthcare connected. She explains how healthcare is entering a second wave of digitisation in Asia.
There is a simple reason why healthcare stocks on the SGX rose today. Yesterday’s budget was focused firmly on healthcare. Finance minister Heng Swee Keat announced not just an additional S$10.2 billion (US$7.8 million) for healthcare over the next year, he made clear that he was committed to the sector.
A new paper from KPMG looks at the disconnect between consumer expectations and the current healthcare experience of patients in Australia.
Gan Kim Yong, Singapore’s minister for health, explains why integrated care is important in the context of an ageing population.
my images


Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices